Last reviewed · How we verify
Elironrasib
Elironrasib is a Small molecule drug developed by Revolution Medicines, Inc.. It is currently in Phase 1 development. Also known as: RMC-6291.
Elironrasib is being studied in clinical trials for various types of solid tumors, including non-small cell lung cancer and colorectal cancer. Elironrasib is one of the RAS(ON) inhibitors being investigated in combination with ivonescimab in a Phase 1/2 study for solid tumors.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Elironrasib |
|---|---|
| Also known as | RMC-6291 |
| Sponsor | Revolution Medicines, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors (PHASE1, PHASE2)
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elironrasib CI brief — competitive landscape report
- Elironrasib updates RSS · CI watch RSS
- Revolution Medicines, Inc. portfolio CI
Frequently asked questions about Elironrasib
What is Elironrasib?
Who makes Elironrasib?
Is Elironrasib also known as anything else?
What development phase is Elironrasib in?
Related
- Manufacturer: Revolution Medicines, Inc. — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: RMC-6291
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing